Novo Nordisk's Ozempic and Wegovy at the moment are out there following shortages

Packs of syringes of the drugs Wegovy, Ozempic and Mounjaro in a shop in Mitte, Germany, July 11, 2024.

Picture Alliance | Picture Alliance | Getty Images

All doses of Novo NordiskThe wildly popular weight loss drug Wegovy and the diabetes drug Ozempic are now available in the United States, according to an update to the U.S. Food and Drug Administration's drug shortage database on Wednesday.

This is a sign that Novo Nordisk's efforts to increase supply of these weekly medications are starting to pay off as demand continues to skyrocket in the US

According to an earlier update, the lowest dose of Wegovy – 25 milligrams – was still in short supply.

Several doses of semaglutide, the active ingredient in Wegovy and Ozempic, have been on the FDA's shortage list since early 2022.

Wednesday's update suggests the FDA could remove the blockbuster shots from its shortage list entirely, which could prevent manufacturing pharmacies from making customized and often cheaper versions of these brand-name drugs.

In a statement, Novo Nordisk said all doses of Wegovy and Ozempic will be shipped to wholesalers on a regular basis. The Danish drugmaker said the FDA's update was the result of the company's significant investments in expanding production capacity and “continuous communication” with the agency.

Still, Novo Nordisk said patients may not always be able to fill their prescriptions immediately at a particular pharmacy, even if a drug is listed as available.

“Our deliberate approach to gradually increase supply in the US market is working,” Novo Nordisk said. “We will continue to prioritize continuity of patient care and closely monitor market dynamics while prescribing trends.”

It comes a week after Novo Nordisk asked the FDA to stop compounding pharmacies from making unapproved versions of Wegovy and Ozempic, arguing that the drugs are too complex for those manufacturers to produce safely.

Earlier this month, the FDA removed the active ingredient tirzepatide from the market Eli LillyThe weight loss drug Zepbound and the diabetes drug Mounjaro were removed from the shortage list. But a trade group representing some drug makers sued the FDA, prompting the agency to say it would reconsider its decision to remove tirzepatide from its shortage list.